MedTrace Logo

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

NCT05626634 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-12-03

No results posted yet for this study

Summary

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.

Conditions

  • Developmental and Epileptic Encephalopathy
  • Dravet Syndrome
  • Lennox-Gastaut Syndrome

Interventions

DRUG

LP352, bexicaserin

LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube

Sponsors & Collaborators

  • Longboard Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dennis J Dlugos, MD · Children's Hospital of Philadelphia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2024-12-20
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05626634 on ClinicalTrials.gov